



## Synthesis and biological evaluation of novel steroid-modified ether phospholipids

Haralabos C. Karantonis<sup>a</sup>, Emmanuel N. Pitsinos<sup>b</sup>, Smaragdi Antonopoulou<sup>c</sup>,  
Elias A. Couladouros<sup>b,d</sup>, Constantinos A. Demopoulos<sup>a,\*</sup>

<sup>a</sup> Laboratory of Biochemistry, Faculty of Chemistry, National and Kapodistrian University of Athens, Panepistimioupolis, GR-157 71 Athens, Greece

<sup>b</sup> Laboratory of Organic and Bio-Organic Chemistry, Institute of Physical Chemistry, NCSR "DEMOKRITOS", Aghia Paraskevi, P.O. Box 60228, GR-153 10 Athens, Greece

<sup>c</sup> Department of Science of Dietetics-Nutrition, Harokopio University, 70 El. Venizelou Street, GR-176 71 Athens, Greece

<sup>d</sup> Chemistry Laboratories, Agricultural University of Athens, Iera Odos 75, GR-118 55 Athens, Greece

Received 10 September 2004; received in revised form 17 December 2004; accepted 22 July 2005

### Abstract

Platelet activating factor is one of the most potent inflammatory ether phospholipid mediators known and structurally modified analogues are of considerable interest as potential therapeutic preparations. Inspired by the proposed structure for a novel endogenous hydroxy-PAF analogue isolated recently from gingival crevicular fluid, we designed and prepared two novel steroid-modified ether phospholipids. These two novel compounds exhibit marked chemical and biological similarities to their endogenous prototype and they antagonize it being less active in inducing washed platelet aggregation through PAF receptors.

© 2005 Elsevier Ireland Ltd. All rights reserved.

**Keywords:** Steroid ether phospholipids; Platelets; Platelet activating factor; PAF-acetylhydrolase; Periodontal disease

### 1. Introduction

Platelet-activating factor (1-*O*-alkyl-2-acetyl-*sn*-glycero-3-phosphocholine, PAF) occurs naturally in cell membranes and is one of the most potent inflammatory ether phospholipid mediators known (Blank et al.,

1981; Demopoulos et al., 1979; Montrucchio et al., 2000). PAF (1, Fig. 1) plays an important role in a number of physiological and pathological processes, such as allergy, hypotension, anaphylaxis, thrombosis, ischemia, acute infections in transplantation, nephritis, gastric ulcer, etc. (Snyder, 1987). Activated inflammatory cells challenged by bacterial lipopolysaccharides produce and secrete inflammatory mediators like PAF (Jakubowski et al., 2004), which is believed to be a key regulator of various diseases like periodontal disease (Antonopoulou et al., 2003). Moreover, PAF has been shown to stimulate platelet degranulation and aggregation (Snyder et al., 1989), to cause the contraction of smooth muscles, bronchoconstriction, and coronary

**Abbreviations:** Ac, acetyl; Bn, benzyl; LPC, lysophosphatidylcholine; PAF, platelet-activating factor; Ph, phenyl; SM, sphingomyelin; TBAF, tetrabutylammonium fluoride; TBDPS, tert-butyldiphenylsilyl; THF, tetrahydrofuran

\* Corresponding author. Present address: 39 Anafis Str., GR-113 64 Athens, Greece. Tel.: +30 210 7274265; fax: +30 210 7274265.

E-mail address: [demopoulos@chem.uoa.gr](mailto:demopoulos@chem.uoa.gr) (C.A. Demopoulos).